Intravenous administration of magnesium and potassium solution lowers energy levels and increases success rates electrically cardioverting atrial fibrillation

J Cardiovasc Electrophysiol. 2012 Jan;23(1):54-9. doi: 10.1111/j.1540-8167.2011.02146.x. Epub 2011 Aug 4.

Abstract

Background: External biphasic electrical cardioversion (CV) is a standard treatment option for patients suffering from acute symptoms of atrial fibrillation (AF). Nevertheless, CV is not always successful, and thus strategies to increase the success rate are desirable.

Objective: The purpose of this study was to evaluate the effect of intravenously administered K/Mg solution on the biphasic CV energy threshold and success rate to restore sinus rhythm (SR) in patients with AF.

Methods: The study consisted of 170 patients with persistent AF. The patients were randomly assigned to undergo biphasic CV either with (n = 84) or without (n = 86) pretreatment with K/Mg solution. An energy step-up protocol of 75, 100, and 150 W (J) was used.

Results: Biphasic CV of AF was effective in 81 (96.4%) patients in the pretreatment and 74 (86.0%) patients in the control group (P = 0.005). The effective energy level required to achieve SR was significantly lower in the pretreated group (140.8 ± 26.9 J vs 182.5 ± 52.2 J, P = 0.02). No K/Mg-solution-associated side effects such as hypotension or bradycardia were observed.

Conclusion: Administration of K/Mg solution positively influences the success rate of CV in patients with persistent AF. Furthermore, significantly less energy is required to successfully restore SR and therefore K/Mg pretreatment may facilitate SR restoration in patients undergoing CV for AF.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Combined Modality Therapy
  • Defibrillators*
  • Electric Countershock / adverse effects
  • Electric Countershock / instrumentation*
  • Female
  • Germany
  • Humans
  • Infusions, Intravenous
  • Magnesium / administration & dosage*
  • Magnesium / adverse effects
  • Male
  • Middle Aged
  • Potassium / administration & dosage*
  • Potassium / adverse effects
  • Treatment Outcome

Substances

  • Magnesium
  • Potassium